Can-Fite Biopharma Ltd Sponsored ADR (Israel) (CANF)
0.1803
-0.0602 (-25.03%)
NYSE · Last Trade: Dec 24th, 5:40 PM EST
Detailed Quote
| Previous Close | 0.2405 |
|---|---|
| Open | 0.2000 |
| Bid | 0.1789 |
| Ask | 0.1810 |
| Day's Range | 0.1700 - 0.2023 |
| 52 Week Range | 0.2334 - 2.330 |
| Volume | 3,783,875 |
| Market Cap | 92.99M |
| PE Ratio (TTM) | -18.03 |
| EPS (TTM) | -0.0 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 1,165,368 |
Chart
About Can-Fite Biopharma Ltd Sponsored ADR (Israel) (CANF)
Can-Fite Biopharma Ltd is a biopharmaceutical company that focuses on the development of innovative therapies for the treatment of cancer and other serious diseases. The company leverages its proprietary drug development platform to create targeted molecular medicines, which are designed to treat conditions such as psoriasis, liver disease, and various types of cancer. Can-Fite is dedicated to advancing its clinical trials and bringing promising therapies to market, with an emphasis on improving patient outcomes and addressing unmet medical needs in the pharmaceutical landscape. Read More
News & Press Releases
Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session.
Via Chartmill · December 24, 2025
Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via Chartmill · December 24, 2025
Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps.
Via Chartmill · December 24, 2025
Before the US market kicks off on Wednesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via Chartmill · December 24, 2025
Let's explore the current happenings on the US markets on Wednesday. Below, you'll find the stocks exhibiting unusual volume in today's session.
Via Chartmill · November 19, 2025
As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Via Chartmill · November 18, 2025
Discover the most active stocks in Tuesday's session. Stay informed about the stocks that are generating the most trading volume!
Via Chartmill · November 18, 2025
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via Chartmill · November 18, 2025
Via Benzinga · November 18, 2025
As the US market prepares to open on Tuesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Via Chartmill · November 18, 2025
Via Benzinga · November 18, 2025
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Via Chartmill · September 30, 2025
Via Benzinga · September 30, 2025
Via Benzinga · August 22, 2025
Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis.
Via Chartmill · July 28, 2025
ORLANDO, FLORIDA / ACCESS Newswire / March 28, 2025 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (Nasdaq:BIAF) and Can-Fite BioPharma Ltd. (NYSE American:CANF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, March 29, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Via ACCESS Newswire · March 28, 2025
Let's have a look at what is happening on the US markets on Thursday. Below you can find the stocks with an unusual volume in today's session.
Via Chartmill · March 20, 2025
Via Benzinga · March 19, 2025

ORLANDO, FL / ACCESSWIRE / November 22, 2024 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (Nasdaq:SXTP) and Can-Fite BioPharma Ltd. (NYSE American:CANF)(TASE:CANF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, November 23, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Via ACCESSWIRE · November 22, 2024

ORLANDO, FL / ACCESSWIRE / August 9, 2024 / RedChip Companies will air interviews with OS Therapies Inc. (NYSE American:OSTX) and Can-Fite BioPharma Ltd. (NYSE American:CANF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, August 10, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Via ACCESSWIRE · August 9, 2024

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that its veterinary partner Vetbiolix reported positive results in an osteoarthritis multicenter clinical study in dogs treated with Piclidenoson. Vetbiolix, Can-Fite’s veterinary commercialization partner which is covering all costs associated with veterinary clinical development, concluded successfully the study interim analysis.
By Can-Fite BioPharma Ltd. · Via Business Wire · June 28, 2024

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announces that company scientists came up with breakthrough findings showing that the anti-cancer and protective effects in the liver are conferred via the signalling protein adiponectin. This very important positive cytokine plays a pivotal role in regulating anti-inflammatory, anti-cancer, metabolic and insulin resistance. Namodenoson increases adiponectin production in pre-clinical studies and in humans.
By Can-Fite BioPharma Ltd. · Via Business Wire · June 24, 2024

Via Benzinga · June 14, 2024
